Battaglia G
Servizio di Gastroenterologia ed Endoscopia Digestiva, OO.CC.RR. Venezia, Italy.
Ital J Gastroenterol. 1994 Jan-Feb;26(1 Suppl 1):19-22.
A controlled, double-blind study with nizatidine in gastric ulcer maintenance treatment was recently performed. Univariate analysis of results after 12 months showed that: a) younger patients have a poor outcome (among nizatidine-treated); b) smoking is a risk factor for relapse; c) ulcers of the lesser curvature of the corpus relapsed more frequently than the others. The present work is a more in-depth analysis of the results using the stepwise logistic regression. The study, which involved 241 patients, takes into account the following data: age, sex, family history of ulcer, smoking habits, alcohol consumption, previous ulcer treatment, number of ulcers, ulcer size and location and current drug therapy (nizatidine or placebo). Multivariate analysis showed that treatment (Odds Ratio 2.45), smoking habits (OR 2.35), sex (OR 2.30) and ulcer family history (OR 2.7) are the major risk factors for relapse. Odds Ratios of combined gastric ulcer relapse risk factors were also obtained. It was concluded that nizatidine treatment is significantly better than placebo in maintaining gastric ulcer remission; cigarette smoking was confirmed the most important risk factor for gastric ulcer relapse; male sex and positive ulcer family history also have a negative influence on gastric ulcer outcome.
最近进行了一项关于雷尼替丁用于胃溃疡维持治疗的对照双盲研究。对12个月后的结果进行单因素分析表明:a)年轻患者(在接受雷尼替丁治疗的患者中)预后较差;b)吸烟是复发的一个危险因素;c)胃体小弯侧溃疡比其他溃疡更频繁复发。本研究是使用逐步逻辑回归对结果进行更深入的分析。该研究纳入了241名患者,考虑了以下数据:年龄、性别、溃疡家族史、吸烟习惯、饮酒情况、既往溃疡治疗情况、溃疡数量、溃疡大小和位置以及当前药物治疗(雷尼替丁或安慰剂)。多因素分析表明,治疗(优势比2.45)、吸烟习惯(OR 2.35)、性别(OR 2.30)和溃疡家族史(OR 2.7)是复发的主要危险因素。还得出了合并胃溃疡复发危险因素的优势比。得出的结论是,在维持胃溃疡缓解方面,雷尼替丁治疗明显优于安慰剂;吸烟被确认为胃溃疡复发的最重要危险因素;男性性别和阳性溃疡家族史也对胃溃疡预后有负面影响。